United Therapeutics (UTHR)
(Real Time Quote from BATS)
$270.27 USD
-0.18 (-0.07%)
Updated May 31, 2024 10:32 AM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
United Therapeutics Corporation [UTHR]
Reports for Purchase
Showing records 441 - 460 ( 589 total )
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals - August and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Financials: Across-the-Board Beat and Growth Continues; Reiterate OUTPERFORM and Increasing PT to $133
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of July 28
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q2 Preview: We Anticipate In-Line Financial Results; Reiterate OUTPERFORM and $119 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
July and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
LIFE SCIENCES AND HEALTH CARE - The Week Ahead in Life Sciences - Upcoming Events for the Week of June 30
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Additional Share Buyback Rewards Long- Term Stock Holders; Reiterate OUTPERFORM and $119 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Additional Share Buyback Rewards Long-Term Stock Holders; Reiterate OUTPERFORM and $119 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
LIFE SCIENCES AND HEALTH CARE
Provider: WEDBUSH SECURITIES INC.
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Emerging Pharmaceuticals - May and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 19
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Announces Deal to Develop Humanized Pig Organs for Clinical Transplantation
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Announces Deal to Develop Humanized Pig Organs for Clinical Transplantation. Reiterate OUTPERFORM & $119 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Financials: Despite Transiently Choppy Tyvaso and Adcirca, Growth Remains Intact In Our View; Reiterate OUTPERFORM and $119 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
Q1 Preview: We Anticipate Sales Growth Continued into Q1. Reiterate OUTPERFORM and $119 PT.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: United Therapeutics Corporation
Industry: Medical - Drugs
April and 2014 Catalysts for Emerging Pharmaceuticals
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L